Dublin-listed Open Orphan continues its rapid growth by landing another major contract with a top three pharma group.
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company, has landed its second major contract in recent weeks.
The Dublin-listed company has signed a contract valued at €4.4 million with a global pharmaceutical company to carry out a respiratory syncytial virus (RSV) human challenge study trial.
The study will take place in a London-based quarantine unit owned by Open Orphan’s subsidiary hVIVO and is expected to be completed by the end of the first quarter of next year with the bulk of the revenues coming in 2020.
hVIVO’s unit is Europe’s only commercial 24-bed quarantine clinic with an on-site virology laboratory, meaning the firm is the only one on the continent with the capability to conduct an RSV human challenge study.
“This contract is evidence of the high regard hVivo is held in within the industry and reinforces our position as the world leader in the testing of vaccines and antivirals using human challenge clinical trials”
“This is another exciting new contract win with a new customer for Open Orphan’s subsidiary hvivo as we convert the substantial pipeline that is building up within the company,” Open Orphan chairman Cathal Friel said.
“This contract, with a top three global pharmaceutical company, is evidence of the high regard hVivo is held in within the industry and reinforces our position as the world leader in the testing of vaccines and antivirals using human challenge clinical trials.
“As a group we are focused on winning and delivering high-quality, profitable contracts and this is another example of our delivery against that strategy,” he added.
Last month, Open Orphan won a contract with New York-based Codagenix to conduct a trial into a vaccine for Covid-19.
The trial will evaluate the safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 vaccine candidate in 48 healthy young adult volunteers. It is expected to start in early Autumn, with initial data expected by the end of 2020.
By Stephen Larkin
Published: 10 August, 2020